Despite advancement in molecular research and in our understanding of bladder cancer, (BC) long-term survival rates of patients have remained unchanged for decades.

What is lacking in the currently available model systems? And what are the features in a biological model that make it suitable for developing more effective drugs?

In this factsheet, we introduce to you our portfolio of in vivo BC models and explain how they can advance your drug development.